Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up.
Level 2 - randomized trial
Randomized controlled trial in elderly patients with long-term follow-up
PubMed 22451889 · doi:10.1007/s10517-011-1332-x
What was done
In a randomized comparative study, 79 elderly coronary patients displaying accelerated cardiovascular aging received either standard baseline therapy plus epithalamin (n = 39; 6 courses administered over 3 years) or baseline therapy alone (n = 40). Patients were monitored over a long-term follow-up period (up to 15 years per the title) for cardiovascular aging markers, endurance, metabolic profiles, and mortality.
What was found
The abstract provides no numerical figures, confidence intervals, or specific p-values. The authors report that epithalamin treatment decelerated cardiovascular aging, preserved physical endurance, normalized circadian melatonin secretion, improved carbohydrate and lipid metabolism, and resulted in significantly lower mortality compared with control.
Why it matters
It investigates whether periodic administration of peptide bioregulators can alter hard clinical endpoints, including mortality, in elderly individuals with cardiovascular disease.
Limits
The abstract reports zero numerical data or statistical measures of precision. The sample size is very small (N = 79 total), blinding and randomization methods are unspecified in the abstract, and the text contains an internal inconsistency regarding the peptide tissue source (titular 'pituitary gland' versus 'pineal gland' in the text).
Cited by
- partial A 15-year study by Khavinson administering Epithalamin and Thymalin to nursing home patients showed significant reductions in cardiovascular, infectious, and cancer mortality.